Hispanic Broadcasting
Hispanic Broadcasting Newswire

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 89 in Hispanic Broadcasting

  1. Sector's Smaller Players Show The WayRead the original story w/Photo

    Saturday Jul 4 | Seeking Alpha

    With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing provides a better guide to the state of play than small and mid-cap companies, whose size makes them particularly exposed to general sector trends.

    Comment?

  2. Medicines Company v. Hospira IncRead the original story w/Photo

    Thursday Jul 2 | FindLaw

    Before DYK, WALLACH, and HUGHES, Circuit Judges. Edgar Haug, Frommer Lawrence & Haug LLP, New York, NY, argued for plaintiff-appellant.

    Comment?

  3. Federal Circuit Rules Against The Medicines Company in Angiomax (bivalirudin) Patent LitigationRead the original story

    Thursday Jul 2 | Business Wire

    7,582,727 and 7,598,343 are invalid. On March 31, 2014, the U.S. District Court of Delaware found that all of the asserted claims of the '727 patent and the '343 patent covering Angiomax were valid but not infringed by Hospira's ANDA products.

    Comment?

  4. The Medicines Company Gets Approval For Cangrelor, But Uncertainty RemainsRead the original story w/Photo

    Monday Jun 29 | Seeking Alpha

    It has been a mixed year for The Medicines Company . Last week, the company received FDA approval for Kengreal .

    Comment?

  5. MetaStat, Inc. Announces Douglas A. Hamilton Named President, Chief Executive OfficerRead the original story

    Thursday Jun 18 | Freshnews

    MetaStat, Inc. , announced that Douglas A. Hamilton has been elected as President and Chief Executive Officer of the company. Mr. Hamilton has consulted for the company as acting Chief Financial Officer since August 2014.

    Comment?

  6. Rheumatic diseases: new results from first real-world study show...Read the original story

    Wednesday Jun 10 | Medical News Today

    Hospira, Inc., a global leader in biosimilars, has announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade to Inflectra. The study entitled, "Clinical experience with infliximab biosimilar - switch from Remicade.

    Comment?

  7. Switching from Remicade to Inflectra benefits patients with rheumatic diseasesRead the original story w/Photo

    Wednesday Jun 10 | Medical News

    Hospira, Inc. , a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade to Inflectra. The study entitled, " Clinical experience with infliximab biosimilar switch from Remicade.

    Comment?

  8. New Study: Hospira, Inc. (HSP) - Medical Equipment - Deals and Alliances ProfileRead the original story

    Jun 2, 2015 | PR-inside.com

    The company undertakes the development, manufacturing, and marketing of products that help improve the safety and effectiveness and reduce the cost of patient care. It is a provider of injectable pharmaceutical drugs and infusion technologies.

    Comment?

  9. Hospira Release: Approves First Infliximab Biosimilar In BrazilRead the original story

    Jun 1, 2015 | BioSpace

    The medication will be marketed by Hospira. Hospira also markets and sells biosimilar infliximab in 26 European countries and in for the treatment of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease in adults and children, fistulizing Crohn's disease , colitis and ulcerative rectocolitis.

    Comment?

  10. Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISARead the original story w/Photo

    Jun 2, 2015 | Medical News

    Hospira, Inc. , a global leader in biosimilars, today announced that its partner, Celltrion a global biopharmaceutical company has received approval from ANVISA the National Health Surveillance Agency in Brazil for Remsima , the first biosimilar monoclonal antibody approved for use in Brazil. The medication will be marketed by Hospira.

    Comment?

  11. These 10 stocks ward off June gloomRead the original story w/Photo

    Jun 1, 2015 | USA Today

    Fighting June gloom isn't easy for investors - it's not a great month for stocks. But there is an antidote.

    Comment?

  12. Is Shire A Takeover Target For Pfizer?Read the original story w/Photo

    May 27, 2015 | Seeking Alpha

    Pfizer has identified strategic areas that it wants to target in the next 4 years, including biosimilars and rare diseases. The biosimilar focus helped spur an acquisition of Hospira earlier in 2015, and Shire appears to be positioned as the next acquisition target for Pfizer in rare diseases.

    Comment?

  13. Short Interest in Hospira Decreases By 36.6%Read the original story

    May 27, 2015 | AmericanBankingNews.com

    Hospira was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,240,589 shares, a drop of 36.6% from the April 15th total of 1,958,095 shares, StockRatingsNetwork.com reports.

    Comment?

  14. Hargreaves Services plc Receives Corporate Rating from N+1 SingerRead the original story

    May 26, 2015 | AmericanBankingNews.com

    's stock had its "corporate" rating reaffirmed by equities research analysts at N+1 Singer in a research note issued to investors on Tuesday. Hargreaves Services plc traded down 2.06% on Tuesday, hitting GBX 403.74.

    Comment?

  15. Best And Worst Performing S&P 500 Stocks Year-To-DateRead the original story w/Photo

    May 25, 2015 | Seeking Alpha

    For those looking to catch up on 2015s winners and losers over the long Memorial Day weekend, below is a list of the 40 best and worst performing stocks in the S&P 500 YTD. As shown, Netflix tops the list of winners with a gain of 82.68%, followed by Skyworks at 45.26% and Hospira at 43.98%.

    Comment?

  16. Barclays: Pfenex Is Worth $28/ShareRead the original story

    May 18, 2015 | Benzinga

    In a report published Monday, Barclays analysts initiated coverage of Pfenex, Inc. with an Overweight rating and price target of $28. The analysts believe the stock offers an attractive investment option, given the company's "differentiated platform for the development of biosimilars and complex generics."

    Comment?

  17. Hospira Shareholders Approve Merger Of And Pfizer At Special MeetingRead the original story

    May 13, 2015 | BioSpace

    The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions.

    Comment?

  18. Pfenex Reports First Quarter 2015 Results And Provides Business UpdateRead the original story

    May 13, 2015 | BioSpace

    As we have previously disclosed, under the terms of the collaboration, Pfenex received a in milestone payments along with tiered double digit royalties. Additionally, in the first quarter of 2015 we achieved an important milestone with the initiation of a Phase 1 trial for PF530, our biosimilar candidate to Betaseron.

    Comment?

  19. a Medical supplier files suit against local hospital systemRead the original story w/Photo

    May 11, 2015 | Business Journal

    Hospira Worldwide Inc. has sued Harnett Health System, alleging the non-profit health care provider failed to pay for more than $123,000 in medical supplies. Hospira Worldwide Inc. has filed a lawsuit against Harnett Health System, alleging the nonprofit health care provider failed to pay for more than $123,000 in medical supplies.

    Comment?

  20. Biosimilars Access and Education Taking Center Stage with First Biosimilars in the WingsRead the original story w/Photo

    May 6, 2015 | jdsupra.com

    Two new voices have emerged with goals to help expand patient access and information about biosimilars in the United States - the Biosimilars Forum and the Biosimilars Council, discussed below. Along with these voices, the New York State Bar Association's Food, Drug and Cosmetic Law Section Biologics Law Committee is working with NYSBA's Health Law Section, Committee on Medical Research and Biotechnology , to take a look at and consider legislative changes for state laws regarding substitution, as well as reimbursement and biological analytics.

    Comment?